explore -WSS

explore

author：leisure time 2025-09-28 00:51:06 - browse：2238

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

WSS

5 dead in mass shooting on Caribbean island of St. Vincent: Police

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Sanders wants to replace patents with prizes for drug inventions

hotspot

explore

Bluebird and the case for gene therapy profits

hotspot

Supreme Court strikes down use of affirmative action

When a patient nears the end, a feared therapy can comfort

Walensky prepares to leave CDC — and Congress — behind

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

Heart attack and stroke risk calculators need revising

Eat, drink, but be wary — 4 foods that interact with medications

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Heart attack and stroke risk calculators need revising

Russian court extends detention of American musician

hotspot

New company forms to vet health AI models, root out weaknesses

Rock icon Freddie Mercury pre

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Delta passengers in Vegas fall sick while waiting on flight in triple

Lifetime voting ban for felony convictions struck down in Mississippi

Taylor Swift shares sweet moment with Kobe Bryant's daughter Bianka at Eras Tour concert

focus

focus

focus

leisure time